AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European ...

Extended oral antibiotic prophylaxis eliminated UTIs after robot-assisted radical cystectomy procedures. Prophylactic ...

Obesity in itself is not a contraindication to radical prostatectomy, but it remains a risk factor for poor overall survival. Although obesity increases the technical complexity of radical ...

Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

In early corporate news, AstraZeneca receives EU approval for a bladder cancer therapy, and a subdued housing market leaves MJ Gleeson eyeing adjusted pretax profit at the lower end of current market ...